More about Henry Schein, Inc.
Regulatory Filings for Henry Schein, Inc.
Fundamentals for Henry Schein, Inc.
Debt, Deficits & Disaster: The Bond Market Crisis
Not Wall Street, But AI: The Real Force Democratizing Finance Across America
When Flooding Pays: A New Financial Bet
Breakfast for Life How Local Diners and Hardware Stores are Outsmarting Amazon
Fundamentals for Henry Schein, Inc.
Business Operations:
Sector: HealthcareIndustry: Medical Distribution
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services. The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers. The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
Revenue projections:
Revenues for HSIC are forecasted to decline from last year's levels, prompting caution among investors. When revenues fall, it can have a significant negative impact on the company's bottom line, reducing profitability and making the stock less attractive to risk-averse investors.
Financial Ratios:
| currentRatio | 1.383000 |
|---|---|
| forwardPE | 12.676384 |
| debtToEquity | 71.736000 |
| earningsGrowth | 0.136000 |
| revenueGrowth | 0.077000 |
| grossMargins | 0.311360 |
| operatingMargins | 0.052950 |
| trailingEps | 3.270000 |
| forwardEps | 5.884170 |
HSIC's current ratio of 1.383 shows that the company has ample resources to service its short-term debt. This indicates a solid financial position, as HSIC can rely on its cash reserves and current assets to cover its immediate liabilities without strain.
Henry Schein, Inc.'s Forward PE being in a good range indicates the stock is priced well relative to its earnings. It is not overvalued, leaving space for future growth, making it an appealing option for investors interested in long-term value appreciation.
HSIC's forward EPS surpassing its trailing EPS signals that the company is anticipated to be more profitable this year than last. This growth expectation highlights HSIC's potential for increased earnings and a stronger financial performance in the upcoming year.
Price projections:
Over time, price projections for HSIC have risen steadily, pointing to growing optimism among analysts about the company's future. This upward trend suggests a positive outlook for HSIC's continued growth.
Insider Transactions:
HSIC experienced 8 sell transactions with market price of 76.97249984741211 per share.1 HSIC stock purchases took place, with market price of 65.9000015258789.The increased selling activity around HSIC's current price levels may indicate further downside risk. If this trend continues, the stock's price could face additional declines as selling pressure intensifies.
Recommendation changes over time:
Analysts have maintained a buy bias for HSIC, which could prompt investors to consider the stock as a viable investment. With this positive outlook, HSIC is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst technicals.
Latest Regulatory Filings for SP5
Companies with the best and the worst fundamentals.
Before They Can Walk, They're Invested: How Trump Accounts Are Transforming Financial Culture
The Appalachian Energy Reboot: Inside the Unexpected Nuclear Startup Boom
Theatrical Finance: Credit Unions Use Drama to Attract Youth